To find out more, watch the following video (4:27 min). A link to a transcript of the interview is also provided below. 

SmartTRAK: Hi, this is Sharon O'Reilly. I'm at the Canaccord Conference before the 2025 AAOS, and I ran into Alessandra Pavesio, who's so excited about her company, Doron Therapeutics.

So, Alessandra, why don't you tell us a little bit about the company and some of the exciting new developments.

Alessandra Pavesio: It's always great to see you, Sharon. I love bumping into you and having some really good news to deliver. First of all, what is Doron Therapeutics? It's a management-led spin-off. We really were passionate about a technology that we've developed with Bioventus, and when Bioventus divested from this program for financial considerations, we were able to negotiate a very favorable deal to actually set up a spin-off company and go raise private capital to invest in the program.

The good news is that, yes, we've set up a company. Yes, we have raised private capital. And so now we are really up and running and getting ready to start a Phase III study.

Big milestone that we've accomplished is that we've been recognized by FDA as an RMAT therapy. RMAT means Regenerative Medicine Advanced Therapy. As such, that means attention from senior officials at FDA that are really partnering with you to get this product to market for the patients that we serve. Super excited.

SmartTRAK: Tell us about the product.

AP: So our lead program is called MOTYS. It's placental-derived injectable therapeutic. It's a biological drug that ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with Doron Therpeutics' CEO Alessandro Pavesio, conducted by Sharon O'Reilly, SmartTRAK Founder and CEO.

SmartTRAK will be attending AAOS 2025 this week. Join us at AAOS to explore our solution and discuss our roadmap for expanding into other orthopedic markets. Learn more about our Brand Tracker here or schedule time to Meet with Us at the show!

In this video, SmartTRAK's Erin Dorgan, Senior Analyst, Spine and Orthobiologics, covers some of the latest trends in the Bone Replacement market leading up to this year's AAOS conference.

Click the button below to download SmartTRAK's Bone Replacement Market Outlook article. In it, we discuss key products and compelling clinical evidence that may impact the Bone Replacement Market in 2025 and beyond.

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.

• Expanding Reimbursement for Lymphedema Products 
  • One of the biggest growth drivers for compression therapies in 2025 is expanding reimbursement for the treatment of lymphedema. With more than three million lymphedema patients estimated in the US alone, SmartTRAK expects ... (read more)
• Improving Ease of Use for Compression Garments
  • SmartTRAK expects several companies to develop or refine compression garments in the years ahead with a focus on improving ease of use. With the growing number of patients having access to compression garments day and night, it’s become even more important for ... (read more)
• Dynamic Compression Innovations Improving Portability
  
  • In the world of dynamic compression, portability is the name of the game and SmartTRAK expects to see ... (read more)

Want to stay ahead of the curve in the US compression device market for 2025 and beyond? Industry trends, regulatory changes and new reimbursement codes are shaping the future—are you prepared?

Click the button below to download Jay Merkel’s market outlook article, "Feel the Pressure: Compression Trends for 2025." As SmartTRAK’s senior analyst, Wound, Jay provides an informative analysis of the latest market shifts, including new compression codes and major code revisions set to take effect on April 1, 2025.

SmartTRAK’s new global procedure and brand share analytics tools for the hip and knee markets transform MedTech market intelligence with faster, smarter insights

SmartTRAK, the leading MedTech market intelligence platform in Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapies, is revolutionizing strategic decision-making with the launch of new US and global procedure tools, brand share analytic, and price estimation tools. Designed to save time and reduce reliance on costly, complex datasets, these tools deliver unparalleled speed and depth of market insights for MedTech companies.

Empowering the Hip and Knee Markets with SmartTRAK’s Brand Tracker

Now available for the hip and knee markets, SmartTRAK’s Brand Tracker offers a powerful suite of analytics tools, including dynamic charts, growth analyses, and detailed breakdowns of product and company brand share. Updated quarterly, Brand Tracker highlights five years of trends covering product mix, average price, and market share by facility type. Upcoming expansions will include Interventional Spine and other orthopedic markets in the coming year.

Global Reach with OUS Procedure Tracker

For customers operating internationally, SmartTRAK introduces the OUS Procedure Tracker powered by Quomeda, featuring ...

•  Joint Replacement Procedures Continue Migrating to the ASC Setting
  
  • In 2023, SmartTRAK estimated that approximately 10% of all US hip and knee replacement procedures were performed in an ambulatory surgery center (ASC) setting. This trend shows no signs of slowing down. Based on recent procedure trends data, SmartTRAK projects ... (read more)
  • While procedure volumes at ASCs have risen, Medicare reimbursement rates continue to drop. SmartTRAK tracking of Medicare surgeon reimbursement shows ... (read more)
    
• Technology Trends: Streamlining, Personalization, Outcomes
  
  • Technology trends carrying over from 2024 include streamlining, personalization and outcomes. Some of the new products launching in 2025 are ... (read more)
• Potentially Disruptive Orthobiologic Therapies Coming to Market
  
  • New Orthobiologic injection therapies aim to better manage symptoms and modify disease progression in osteoarthritis (OA) patients. SmartTRAK feels this is ... (read more)
• Eight New Therapies on the Horizon That Could Impact Joint Replacement
  • Delaying surgeries by managing symptoms and  ... (read more)
  • Reducing the number of joint replacements performed: Advanced OA injectable therapies that more effectively target pain management could result in ... (read more)

Curious about the latest trends in the joint replacement market for 2025?    Click below to read her comprehensive market outlook article "Joint Replacement Trends to Watch in 2025" by Lisa Mahan, SmartTRAK's VP of Product Development & IT, Sr. Analyst Total Joints.

Carsten Schroeder, president and CEO of Terumo Neuro, discusses the company’s plans to capture share and become the market leader in neurovascular.

Carsten Schroeder, president and CEO of Terumo Neuro, discusses the company’s rebranding, plans for growth and becoming the market leader in neuroendovascular technologies in an interview with SmartTRAK. Listen to the video below to find out more, including how Terumo plans to innovate and take share via new disease states and markets in addition to its core neurovascular markets (ischemic, hemorrhagic and access).

Click on the video below to watch the interview (32:05 min). A link to download the complete transcript of the interview is available here. For more details, interview topics by timecode are provided below.